Some people with head and neck cancer will now have access to the immunotherapy drug pembrolizumab (Keytruda) on the NHS in England.
A new immunotherapy treatment has been recommended by the National Institute for Health and Care Excellence (NICE) for some adults with small cell lung cancer.
Atezolizumab used in combination with nab-paclitaxel is the first immunotherapy available for triple negative breast cancer.
An immunotherapy and a targeted cancer drug were among the latest batch of NHS approvals from the Scottish Medicines Consortium (SMC).
Leukaemia and head and neck cancer drugs have not been recommended for NHS use in England.
An immunotherapy and chemotherapy combo has been rejected for some adults with small cell lung cancer on the NHS in England.
A treatment option for some people with bladder cancer, currently available through the CDF has been given an initial ‘no’ for routine use in England.
An immunotherapy treatment for triple negative breast cancer has been provisionally rejected for NHS use in England.
A peculiar type of tumour, in an even more peculiar type of animal, could hold some clues to help scientists overcome immunotherapy resistance in humans.
A personalised immunotherapy treatment will now be available in Scotland for some adults living with an aggressive form of lymphoma.